WHO Launches Groundbreaking Online Repository for Evidence-Informed Decision-Making Tools

By HEOR Staff Writer

September 19, 2023

Evidence-Informed Decision-Making

The World Health Organization (WHO) has launched an innovative online repository of Evidence-Informed Decision-Making (EIDM) tools. This pioneering platform, the first of its kind, showcases WHO tools and external tools used by WHO to facilitate knowledge translation. It also highlights partner organisations involved in planning, managing, monitoring, and evaluating the process of evidence use and implementation.

Developed by the Evidence to Policy and Impact Unit of the Research for Health Department in the Science Division, in collaboration with the Evidence-Informed Policy Network (EVIPNet), the repository supports the unit’s EIDM capacity-sharing work. The platform complements the WHO evidence ecosystem framework published last year, specifically focusing on the policy/action cycle.

Navigating the Online Platform

The user-friendly online platform enables users to search and access EIDM methods and tools corresponding to each step of the policy/action cycle. Users can refine their searches using advanced functionalities to filter by document type, language, and publication date. The platform offers tools that span the clinical (or practice), public health, and health system domains.

Currently, the repository houses and maintains 75 tools, with continuous updates as new tools emerge. The Evidence to Policy and Impact Unit plans to actively add more tools to the repository, employing a scoping literature review and other steps.

The ultimate goal of EIDM and the work of EVIPNet is to support WHO staff and Member States in applying rigorous, systematic, and transparent methods for the creation and application of research evidence in their day-to-day work. This will enable the organisation to successfully achieve the “Triple Billion” targets: a billion more people with universal health coverage, a billion more people protected from health emergencies, and a billion more people with better health and well-being.

Reference url

Recent Posts

Koselugo EU Approval: A Milestone in Treating Plexiform Neurofibromas for Adult NF1 Patients

By HEOR Staff Writer

November 7, 2025

European Commission Approves Koselugo for Adult NF1 Patients The European Commission has granted approval for Koselugo (selumetinib), an oral MEK inhibitor developed by Alexion, AstraZeneca Rare Disease, to treat symptomatic, inoperable plexiform neurofibromas in adult patients with neu...
Eloralintide Obesity Treatment: Phase 2 Trial Reveals Significant Weight Loss Potential
Are you wondering about the latest eloralintide obesity treatment options? Eloralintide, a selective amylin receptor agonist, has shown promising results in managing obesity. In a recent phase 2 trial, it led to significant weight loss of up to 20% over 48 weeks in adults with obesity or overweig...
Accelerated UK Clinical Trial Reforms: Enhancing Approvals with AI and Efficiency

By HEOR Staff Writer

November 5, 2025

UK Clinical Trial Reforms Slash Approval Times UK Clinical Trial Reforms have accelerated clinical trial approvals, reducing average times from 91 days to 41 days through risk-proportionate changes at the Medicines and Healthcare produ...